Home > Boards > US Listed > Medical - Drugs >

Arbutus Biopharma Corporation (ABUS)

Add ABUS Price Alert      Hide Sticky   Hide Intro
Moderator: mick
Search This Board: 
Last Post: 4/7/2018 1:07:02 PM - Followers: 86 - Board type: Free - Posts Today: 0

Arbutus Biopharma Corporation







Company Information:

100 - 8900 Glenlyon Parkway
Burnaby, British Columbia
Canada V5J 5J8

Telephone: 604.419.3200
Fax: 604.419.3201


As the fields of genetics, medicine and therapeutics continue to converge, the management of illness at its genetic source by silencing genes via RNA interference (RNAi) holds the very real potential to revolutionize treatment on a scale not seen in decades. Tekmira is one of a handful of biotech companies around the world working to exploit the potential of RNAi to treat disease. And it is from among these unique companies that the next wave of therapeutic breakthroughs will emerge.

 Tekmira is uniquely equipped to become a leading force in the field. Guided by a cohesive vision, the company possesses leading technology capabilities and a solid intellectual property portfolio in the area of lipid-based nucleic acid delivery, known as SNALP (Stable Nucleic Acid Lipid Particles) to deliver siRNAs (small interfering RNAs) as well as other oligonucleotides in the treatment of disease.

With one RNAi drug candidate in clinical development and another in late preclinical development,  plus a pipeline of up to five additional targets made possible through an agreement with RNAi leader Alnylam, Tekmira is well positioned to aggressively advance its product development strategy. In addition to Alnylam, Roche, Merck and Regulus all have access to Tekmira's technology in the delivery of siRNAs and microRNAs.

Finally, broad manufacturing capabilities and a strong capital position permit the company to move forward decisively and build a solid base for both near and longer term growth.




Important Company Highlights: 

LNP Delivery Platform

Tekmira’s Lipid Nanoparticle (LNP) technology represents the most widely adopted RNAi delivery technology to date. Administered intravenously, our LNP delivery technology allows RNAi drugs to be encapsulated in tiny particles made of lipids (fats or oils). These tiny particles – LNP – travel through the bloodstream to target tissues.





Recent News:





Links of importance for those that trade Canadian stocks:




 CNW Group Newswire:

Canadian Insider:

Currency Converter:


Transfer Agent:

CIBC Mellon Trust,
Suite 1600, The Oceanic Plaza,
1066 West Hastings Street,
Vancouver, BC V6E 3X1

Share Structure:   See filings

Investor Relations:

Ian Mortimer
Executive Vice President, Finance and Chief Financial Officer
Telephone: 604.419.3200
Fax: 604.419.3201

Adam Peeler
Investor Relations
The Equicom Group
Telephone: 416.815.0700 x 225 

 Currency Converter:


 8-34-200/ 6 MOS ppo, accum.,R.S.I., PPS, vol 

daily retracement % 
18 mos, black, daily, retrace 3%, pos retrace 5%, retrace 7%, volume, candles, pps, 






 All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn't a sign of endorsement.

 Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ABUS News: Statement of Changes in Beneficial Ownership (4) 04/18/2018 02:27:04 PM
ABUS News: Statement of Changes in Beneficial Ownership (4) 04/13/2018 05:29:26 PM
ABUS News: Current Report Filing (8-k) 04/12/2018 12:31:29 PM
ABUS News: Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018 04/12/2018 12:00:00 PM
ABUS News: Amended Statement of Beneficial Ownership (sc 13d/a) 04/12/2018 08:06:49 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#4953  Sticky Note NEW COMPANY NAME/ ARBUTUS BIOPHARMA CORPORATION/ $ABUS recent news/filings[/b mick 08/06/15 01:42:07 PM
#5175 mick 04/07/18 01:07:02 PM
#5174 mick 02/28/18 12:48:22 PM
#5173 mick 01/23/18 08:22:34 PM
#5172   Arbutus Biopharma Co (ABUS) mick 01/23/18 08:22:22 PM
#5171   I have a good feel for this company manisero66 01/18/18 07:59:15 AM
#5170 mick 12/01/17 06:23:09 AM
#5169 mick 10/08/17 02:11:35 PM
#5168 Inoviorulez 09/25/17 05:09:44 PM
#5167   Arbutus Biopharma Corporation Ubertino 09/22/17 05:30:51 PM
#5166   ALNY announced since early wonder why Abus announced Tdash 09/20/17 01:50:56 PM
#5165   $ALNY had nice news...which uses $ABUS's LNPs so JDoggs_Money 09/20/17 10:53:34 AM
#5164   Any news what's going on with ABUS? piecesofeight 09/20/17 09:54:12 AM
#5163   Maybe they'll hold managements feet to the fire wsgalvanize 09/15/17 01:14:18 PM
#5162   Svf Investments (uk) Ltd has filed a new wiltonio 09/15/17 06:13:30 AM
#5161   ah 1 ????? mick 08/31/17 03:21:16 PM
#5160   Arbutus Biopharma Co (ABUS) mick 08/31/17 03:20:01 PM
#5159 Inoviorulez 08/22/17 03:21:40 AM
#5158   Arbutus Biopharma Co (ABUS) mick 07/09/17 11:44:36 AM
#5157   ABUS News: Current Report Filing (8-k) 05/22/2017 07:01:27 AM mick 05/24/17 07:36:05 AM
#5156   Arbutus Biopharma Co (ABUS) mick 05/24/17 07:35:58 AM
#5155   RTW INVESTMENTS, LLC has filed a new 13G, wiltonio 05/17/17 05:30:47 PM
#5154   Arbutus Biopharma Co (ABUS) mick 04/08/17 01:18:50 PM
#5153   I've been disappointed ever since I bought in rivervalley 03/29/17 03:29:37 PM
#5152   ...what a huge disappointment this stock has been.I wsgalvanize 03/23/17 01:24:26 PM
#5151   ABUS News: Annual Report (10-k) 06:09 AM mick 03/22/17 06:08:10 PM
#5150   Arbutus Biopharma Co (ABUS) mick 03/22/17 06:08:05 PM
#5149   ABUS News: Current Report Filing (8-k) 03/16/2017 05:31:17 PM mick 03/17/17 11:43:49 AM
#5148   Arbutus Biopharma Co (ABUS) mick 03/17/17 11:43:39 AM
#5147   Nice news, and good to finally see some rivervalley 03/17/17 10:01:07 AM
#5146   Arbutus (ABUS) to Buy from Neutral. Analyst Gbola misterheat 03/17/17 07:39:39 AM
#5145   $80 million contract is 45% of ABUS present misterheat 03/17/17 07:19:57 AM
#5144   $ABUS Arbutus Says Alexion Will Pay $7.5M Upfront, misterheat 03/17/17 07:18:31 AM
#5143   Halted Lunacy aka John Galt 03/16/17 05:00:52 PM
#5142   ABUS News: Current Report Filing (8-k) 02/09/2017 04:31:37 PM mick 02/22/17 12:07:30 PM
#5141   Arbutus Biopharma Co (ABUS) mick 02/22/17 12:07:22 PM
#5140   Arbutus Biopharma Co (ABUS) mick 12/31/16 07:18:49 PM
#5139   ABUS News: Securities Registration Statement (simplified Form) (s-3) 12/23/2016 mick 12/31/16 07:18:36 PM
#5138   vol can precede price let's just hope what rivervalley 12/30/16 04:09:24 PM
#5137   We'll see how this trades in the next wsgalvanize 12/30/16 04:04:55 PM
#5136   Sure hope its better bernice, this has been rivervalley 12/30/16 12:53:36 PM
#5135   Could be. I think a big "Seller" is bernice 12/30/16 12:41:44 PM
#5134   Do you think that vol will translate into rivervalley 12/30/16 12:35:41 PM
#5133   big volume today. bernice 12/30/16 11:28:30 AM
#5132   good they can bite their nails for 29 11JR11 12/23/16 10:31:05 AM
#5131   more tax loss selling today. bernice 12/23/16 10:19:57 AM
#5130   should pop just on this tommorrow, they have 11JR11 12/21/16 01:27:21 PM
#5129   ha better than 5 to 1 buys vs 11JR11 12/21/16 11:54:44 AM
#5128   over 60k on 255 now this is getting 11JR11 12/21/16 11:52:07 AM
#5127   lots of buyers waiting on 2.55 may have 11JR11 12/21/16 11:48:08 AM
#5126   buys out pacing sells more than 2 to 11JR11 12/21/16 11:44:41 AM